Longeveron Presents Additional CLEAR MIND Phase 2a Data at AAIC 2026 Poster Session Monday July 13: Laromestrocel Stem Cell Therapy Stabilizes Brain Inflammation in Key Gray and White Matter Regions in Patients With Mild Alzheimer's Disease as Assessed by Free Water MRI, Providing Support for a Durable Anti-Inflammatory Mechanism of Action With Potential Blood Biomarker Correlates; CLEAR MIND Phase 2a Results Previously Published in Nature Medicine in March 2025
Longeveron (NASDAQ: LGVN) presented additional CLEAR MIND Phase 2a clinical data analysis for laromestrocel, its investigational allogeneic mesenchymal stem cell (Medicinal Signaling Cell) therapy, at AAIC 2026 in London on Monday July 13, 2026 from 7:30 AM-4:15 PM BST. The poster titled 'Laromestrocel Stabilizes Brain Inflammation In Key Alzheimer's Disease Gray And White Matter Regions As Assessed Using Free Water MRI' extends the CLEAR MIND Phase 2a program that Longeveron first published in Nature Medicine in March 2025. Free water MRI, a diffusion-based imaging technique that quantifies extracellular water and correlates with neuroinflammation, showed that laromestrocel-treated patients maintained stable brain inflammation levels in key gray and white matter regions relevant to Alzheimer's disease pathology. The findings support a clinically relevant and durable anti-inflammatory mechanism of action for laromestrocel and indicate potential blood biomarker correlates for tracking treatment response. Laromestrocel is administered as an intravenous infusion; the program targets neuroinflammation as a disease-modifying mechanism distinct from amyloid and tau approaches.